WO2002098891A3 - Gad utiles en tant que modificateurs de la voie p53 et methodes d'utilisation - Google Patents

Gad utiles en tant que modificateurs de la voie p53 et methodes d'utilisation Download PDF

Info

Publication number
WO2002098891A3
WO2002098891A3 PCT/US2002/017465 US0217465W WO02098891A3 WO 2002098891 A3 WO2002098891 A3 WO 2002098891A3 US 0217465 W US0217465 W US 0217465W WO 02098891 A3 WO02098891 A3 WO 02098891A3
Authority
WO
WIPO (PCT)
Prior art keywords
pathway
methods
gads
modifiers
modulators
Prior art date
Application number
PCT/US2002/017465
Other languages
English (en)
Other versions
WO2002098891A2 (fr
Inventor
Lori Friedman
Gregory D Plowman
Marcia Belvin
Helen Francis-Lang
Danxi Li
Roel P Funke
Original Assignee
Exelixis Inc
Lori Friedman
Gregory D Plowman
Marcia Belvin
Helen Francis-Lang
Danxi Li
Roel P Funke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Lori Friedman, Gregory D Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P Funke filed Critical Exelixis Inc
Priority to AU2002314887A priority Critical patent/AU2002314887A1/en
Publication of WO2002098891A2 publication Critical patent/WO2002098891A2/fr
Publication of WO2002098891A3 publication Critical patent/WO2002098891A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

On a identifié des gènes GAD humains en tant que modulateurs de la voie p53, ces derniers étant donc des cibles thérapeutiques pour les troubles associés à un dysfonctionnement de p53. Des méthodes d'identification de modulateurs de p53, comprenant le criblage d'agents modulant l'activité de GAD sont également présentées.
PCT/US2002/017465 2001-06-05 2002-06-03 Gad utiles en tant que modificateurs de la voie p53 et methodes d'utilisation WO2002098891A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002314887A AU2002314887A1 (en) 2001-06-05 2002-06-03 Gads as modifiers of the p53 pathway and methods of use

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US29607601P 2001-06-05 2001-06-05
US60/296,076 2001-06-05
US32860501P 2001-10-10 2001-10-10
US60/328,605 2001-10-10
US35725302P 2002-02-15 2002-02-15
US60/357,253 2002-02-15
US36119602P 2002-03-01 2002-03-01
US60/361,196 2002-03-01

Publications (2)

Publication Number Publication Date
WO2002098891A2 WO2002098891A2 (fr) 2002-12-12
WO2002098891A3 true WO2002098891A3 (fr) 2003-05-30

Family

ID=27501675

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2002/017457 WO2002098889A2 (fr) 2001-06-05 2002-06-03 Map3ks utiles en tant que modificateurs de la voie p53 et methodes d'utilisation
PCT/US2002/017460 WO2002098468A1 (fr) 2001-06-05 2002-06-03 Slc13a utiles en tant que modificateurs de la voie p53 et methodes d'utilisation
PCT/US2002/017739 WO2002099068A2 (fr) 2001-06-05 2002-06-03 Lce utilises comme modificateurs de la voie p53 et procede d'utilisation
PCT/US2002/017465 WO2002098891A2 (fr) 2001-06-05 2002-06-03 Gad utiles en tant que modificateurs de la voie p53 et methodes d'utilisation

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PCT/US2002/017457 WO2002098889A2 (fr) 2001-06-05 2002-06-03 Map3ks utiles en tant que modificateurs de la voie p53 et methodes d'utilisation
PCT/US2002/017460 WO2002098468A1 (fr) 2001-06-05 2002-06-03 Slc13a utiles en tant que modificateurs de la voie p53 et methodes d'utilisation
PCT/US2002/017739 WO2002099068A2 (fr) 2001-06-05 2002-06-03 Lce utilises comme modificateurs de la voie p53 et procede d'utilisation

Country Status (5)

Country Link
EP (2) EP1402051A4 (fr)
JP (2) JP2004532638A (fr)
AU (1) AU2002314887A1 (fr)
CA (2) CA2448112A1 (fr)
WO (4) WO2002098889A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2012233044B2 (en) * 2002-11-22 2015-09-03 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
AU2003297318A1 (en) * 2002-12-20 2004-07-22 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
DE10316701A1 (de) * 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. Humane Nukleinsäuresequenzen aus Bronchialkarzinomen
JPWO2005005665A1 (ja) * 2003-07-11 2006-11-09 萬有製薬株式会社 Ｌｃｅによる肥満治療に有効な化合物の評価方法
EP1677739A4 (fr) * 2003-09-04 2008-07-23 Immusol Inc Methodes permettant d'identifier des agents qui inhibent la croissance des cellules cancereuses
WO2005083425A2 (fr) * 2004-02-26 2005-09-09 Bayer Healthcare Ag Agents de diagnostic et de therapie destines aux maladies associees a la proteine kinase 13 activee par un mitogene (map3k13)
CN101120433B (zh) 2004-06-04 2010-12-08 伊利诺伊大学评议会 用于制造并组装可印刷半导体元件的方法
MY149292A (en) 2007-01-17 2013-08-30 Univ Illinois Optical systems fabricated by printing-based assembly
TWI671811B (zh) 2009-05-12 2019-09-11 美國伊利諾大學理事會 用於可變形及半透明顯示器之超薄微刻度無機發光二極體之印刷總成
WO2012097163A1 (fr) 2011-01-14 2012-07-19 The Board Of Trustees Of The University Of Illinois Réseau de composants optiques ayant une courbure réglable
US9765934B2 (en) 2011-05-16 2017-09-19 The Board Of Trustees Of The University Of Illinois Thermally managed LED arrays assembled by printing
WO2012167096A2 (fr) 2011-06-03 2012-12-06 The Board Of Trustees Of The University Of Illinois Réseau d'électrodes de surface conformables, multiplexées de manière active et à haute densité, pour un interfaçage avec le cerveau
KR101979354B1 (ko) 2011-12-01 2019-08-29 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 프로그램 변형을 실행하도록 설계된 과도 장치
CN114181944B (zh) * 2020-09-14 2023-10-03 中国科学院动物研究所 突变基因及构建短肢性侏儒症小型猪模型的方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837812A (en) * 1991-02-22 1998-11-17 Amrad Corporation Limited Human islet, human brain and mouse brain glutamic acid decarboxylase GAD polypeptides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405941A (en) * 1993-04-15 1995-04-11 National Jewish Center For Immunology And Respiratory Medicine MEKK protein, capable of phosphorylating MEK
US5554523A (en) * 1994-03-01 1996-09-10 Children's Hospital Of Philadelphia Nucleic acid sequences encoding human leucine-zipper protein-kinase
WO1999041385A1 (fr) * 1998-02-13 1999-08-19 Cadus Pharmaceutical Corporation Proteines mekk1 et leurs fragments destines a etre utilises dans la regulation d'une apoptose
WO2001034643A1 (fr) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 24 proteines humaines secretees
WO1999047686A2 (fr) * 1998-03-16 1999-09-23 Cadus Pharmaceutical Corporation Proteines humaines mekk, molecules d'acides nucleiques et procedes d'utilisation correspondants
WO2000055330A1 (fr) * 1999-03-18 2000-09-21 The University Of Bristol Elongase d'acides gras polyinsatures tires de caenorhabiditis elegans
AU4483500A (en) * 1999-04-23 2000-11-10 Incyte Genomics, Inc. Human membrane-associated proteins
WO2001007586A2 (fr) * 1999-07-22 2001-02-01 The University Of British Columbia Enzyme biosynthetique d'acides gras a chaines longues de plantes
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1299538A2 (fr) * 2000-06-20 2003-04-09 Incyte Genomics, Inc. Proteines secretees
WO2002014355A2 (fr) * 2000-08-11 2002-02-21 Merck Patent Gmbh Nouvelles protéines mekk
US7297523B2 (en) * 2000-11-29 2007-11-20 Xenon Pharmaceuticals Inc. Human elongase genes and uses thereof
CA2437571A1 (fr) * 2001-02-06 2002-08-15 Incyte Genomics, Inc. Recepteurs et proteines associees aux membranes
WO2002062974A2 (fr) * 2001-02-08 2002-08-15 Bayer Aktiengesellschaft Regulation de la proteine humaine elongase hselo1
WO2002062975A2 (fr) * 2001-02-08 2002-08-15 Bayer Aktiengesellschaft Regulation de la proteine humaine du type elongase hselo1
WO2002096943A1 (fr) * 2001-05-25 2002-12-05 Asahi Kasei Kabushiki Kaisha Genes activant le stat6
AU2003231531A1 (en) * 2002-04-24 2003-11-10 Incyte Corporation Kinases and phosphatases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837812A (en) * 1991-02-22 1998-11-17 Amrad Corporation Limited Human islet, human brain and mouse brain glutamic acid decarboxylase GAD polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE GENCORE *

Also Published As

Publication number Publication date
CA2448112A1 (fr) 2002-12-12
EP1402051A2 (fr) 2004-03-31
WO2002098889A3 (fr) 2003-03-27
EP1402262A4 (fr) 2005-05-11
WO2002099068A2 (fr) 2002-12-12
EP1402051A4 (fr) 2005-08-17
WO2002098468A1 (fr) 2002-12-12
EP1402262A2 (fr) 2004-03-31
WO2002098891A2 (fr) 2002-12-12
CA2449479A1 (fr) 2002-12-12
JP2004532638A (ja) 2004-10-28
WO2002099068A3 (fr) 2003-12-04
JP2005514906A (ja) 2005-05-26
WO2002098889A2 (fr) 2002-12-12
AU2002314887A1 (en) 2002-12-16

Similar Documents

Publication Publication Date Title
WO2002099053A3 (fr) Slc22a utilises comme modificateurs de la voie p53 et procedes d'utilisation
WO2002099074A8 (fr) Slc7s utilises en tant que modificateurs de la voie p53 et procedes d'utilisation correspondants
WO2003074674A3 (fr) Genes msra utilises en tant que modificateurs de la voie p53 et procedes d'utilisation associes
WO2003014301A3 (fr) Hprp4 en tant que modificateurs de la voie de passage p53 leurs et methodes d'utilisation
WO2002098891A3 (fr) Gad utiles en tant que modificateurs de la voie p53 et methodes d'utilisation
WO2003035833A3 (fr) Modificateurs de la voie de passage de p53 et leurs procedes d'utilisation
WO2003051905A3 (fr) Taojik utilises en tant que modificateurs de la voie beta-catenine et procedes d'utilisation associes
WO2002099043A8 (fr) P5crs identifies comme des modificateurs de la voie p53 et procedes d'utilisation
WO2003035831A3 (fr) Lrrcaps en tant que modificateurs de la voie de passage p53 et leurs procedes d'utilisation
WO2004065542A3 (fr) Mat2a utilises comme modificateurs de la voie p53 et procedes d'utilisation
WO2003052068A3 (fr) Genes mbcat agissant comme modificateurs du mecanisme d'action de la beta-catenine et methodes d'utilisation
WO2003052066A3 (fr) Klcs utilises en tant que genes modificateurs de la voie p53 et procedes d'utilisation correspondant
WO2004024881A3 (fr) Ldlr utilise en tant que modificateur de la voie p53 et procedes d'utilisation associes
WO2003052070A3 (fr) Genes vps41 en tant que modificateurs de la mort cellulaire et procedes d'utilisation associe

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP